Q-pharma Inc. positioned to gain major share of toothpaste market with acquisition of key U.S. patent.EDMONDS, Wash.--(BW HealthWire)--May 22, 1997--The company announced today the completion of the purchase of U.S. Patent 4,654,373 titled "Pharmaceutical Formulation Pharmaceutical formulation, in pharmaceutics, is the process in which different chemical substances are combined to a pure drug substance to produce a final medicinal product. Containing Coenzyme coenzyme (kō-ĕn`zīm), any one of a group of relatively small organic molecules required for the catalytic function of certain enzymes. Q-10 Suitable for Topical Administration" from Italfarmaco S.A., Lugano, Switzerland. Q-pharma is presently formulating, and expects to bring to market, an all new toothpaste that will be covered by this patent. The patent, along with current research studies conducted in the U.S., Japan and Europe, have shown that an effective amount of Coenzyme Q-10 in paste form, when applied topically to inflamed gum tissue, halts gingivitis gingivitis (jĭn'jəvī`tĭs), inflammation of the gums. It may be acute, subacute, chronic, or recurrent. The gums usually become red, swollen, and spongy, and bleed easily. and alleviates periodontitis periodontitis Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues. . The company believes that this product, aptly named "Q-dent(TM), The Coenzyme Q-10 Toothpaste," and because of its uniqueness in eliminating serious gum problems, will be able to gain a major share of the present toothpaste market. This market, now $1.7 billion, is expected to be over $2 billion by the year 2000. Q-pharma concludes that the industry giants, such as Colgate-Palmolive, Proctor and Gamble and Cheeseborough-Pond, will be facing formidable competition in Q-dent when it comes to the marketplace. A Reg A offering of 1.4 million shares, which was deemed effective May 5, 1997, is currently being offered on behalf of the company by offering circular Offering Circular An abbreviated prospectus for a new security listing. Delivered to individuals and brokerage houses, these documents are issued to arouse interest in the new issue. Notes: An offering circular allows investors to access information regarding a new issue. to investors. CONTACT: Q-pharma Inc. Joseph S. Baba, 888/742-7687 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion